Bull Flag consolidation. - Double top rejected at long term resistance of $9.09 - Fell through $7.31 support - Bouncing off lower falling channel. - Multiple falling wedges inside large falling channel. Target: $11.32 Stop Loss: $5.65
Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B....
Shareholders of $MACK are getting a $20 million special dividend. The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following the payment date. Stockholders of record on the record date who...
MACK watching the ascending triangle for a break of 3.38
MACK had a huge run forming a fallen angel pattern recently & now seems getting ready for a second phase run. We would like to see break out of MA100 for long entry, and our first target is 5.93
Earlier today $MACK spiked towards the 6.50 area (half dollar resistance) and then on the daily it spiked into the 200ma and failed. It has pretty good resistance in that area so i'm looking to see if it will spike up towards the 6.50's area tomorrow and then i'll go short!
Nice breakout of the week resistance with appropriate stop-loss and good target near 8.70
With new info from an FDA approval of the drugs could mean a small buy up to the next fib level looking for possible 7.0 in the next week to 3 weeks
Bounced off 786 support and now retesting the previous swing high at 6.64, may retrace back to try 618, potential chance to go long.
Merrimack Pharmaceuticals, Inc. (MACK) a biopharmaceutical company is engaged in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. MACK is currently trading around $7.12 in a 52 week range of $2.05-$7.65. The company’s stock has been under performing the...
3 different people within the company bought shares at around $3.70 on 11/27 and 11/29. Although the stock has already rallied, I think there is some more left in it. www.insidermonkey.com A total of 289,000 shares were purchased by insiders last week, close to a $1 million